COMPASS Pathways plc 8-K

What Happened
COMPASS Pathways plc (filed July 7, 2026) announced 26‑week results from Part B of its Phase 3 COMP006 trial for COMP360 (synthetic psilocybin) in treatment‑resistant depression (TRD) and posted an investor presentation (Exhibit 99.1). The trial dosed 581 participants across North America and Europe; in the 25 mg arm 39% achieved a clinically meaningful ≥25% reduction in MADRS by Week 6 that was maintained through Week 26. COMP006’s findings build on earlier positive COMP005 results and the company says a rolling NDA review with the FDA is underway, with final submission on track for Q4 2026 and a potential launch in H1 2027 pending FDA approval and DEA rescheduling.

Key Details

• Trial size and arms: COMP006 randomized, double‑blind, 581 dosed (25 mg: n=296; 10 mg: n=142; 1 mg: n=143). COMP005 earlier dosed 258 (25 mg: n=171; placebo: n=87).
• Efficacy: 39% in the 25 mg arm reached ≥25% MADRS reduction at Week 6 and maintained benefit to Week 26; COMP005 showed 25% following a single dose. Retreatment in Part B led to nearly 30% of Week‑6 responders later achieving remission.
• Safety: Generally well tolerated; most treatment‑emergent adverse events were transient and occurred on dosing day. Most common AEs: nausea, headache, anxiety, visual hallucination. Serious adverse events over 26 weeks: 6.3% (1 mg) vs 5.7% (25 mg).
• Regulatory/next steps: Rolling NDA review with FDA underway; final NDA submission planned Q4 2026. Company anticipates potential commercial launch in H1 2027 if approved and rescheduling occurs.

Why It Matters
These results provide longer‑term (26‑week) efficacy and safety data from a large Phase 3 cohort in a highly chronic TRD population, reinforcing prior positive findings from COMP005 and supporting the company’s regulatory timeline toward an NDA and potential U.S. launch. For investors, the data and the on‑track regulatory milestones are material to COMPASS’s pathway from clinical‑stage toward potential commercial revenue, but approval and timing remain contingent on FDA review and DEA scheduling.